Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker FENC
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Oct 19, 2026 | SCHEDULE 13G/A (amended) | FENC Fennec Pharmaceuticals Inc. | AIGH Capital Management LLC | 2.50M | 7.1% | SCHEDULE 13G/A ↗ |
| Oct 19, 2026 | SCHEDULE 13G/A (amended) | FENC Fennec Pharmaceuticals Inc. | Orin Hirschman | 2.50M | 7.1% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | FENC Fennec Pharmaceuticals Inc. | Frederick Tucker Golden | 1.89M | 5.4% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | FENC Fennec Pharmaceuticals Inc. | Solas Capital Management, LLC | 1.89M | 5.4% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | FENC Fennec Pharmaceuticals Inc. | John S. Clark II | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | FENC Fennec Pharmaceuticals Inc. | Southpoint GP, LLC | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | FENC Fennec Pharmaceuticals Inc. | Southpoint GP, LP | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | FENC Fennec Pharmaceuticals Inc. | Southpoint Capital Advisors LLC | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | FENC Fennec Pharmaceuticals Inc. | Southpoint Capital Advisors LP | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | FENC Fennec Pharmaceuticals Inc. | Southpoint Master Fund, LP | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | FENC Fennec Pharmaceuticals Inc. | Rosalind Master Fund L.P. | 3.19M | 9.2% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | FENC Fennec Pharmaceuticals Inc. | Aharon Gil | 3.19M | 9.4% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | FENC Fennec Pharmaceuticals Inc. | Salamon Steven A J | 3.25M | 9.4% | SCHEDULE 13G/A ↗ |
| Aug 13, 2026 | SCHEDULE 13G/A (amended) | FENC Fennec Pharmaceuticals Inc. | Rosalind Advisors, Inc. | 3.32M | 9.6% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | FENC Fennec Pharmaceuticals Inc. | Frederick Tucker Golden | 2.48M | 7.2% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | FENC Fennec Pharmaceuticals Inc. | Solas Capital Management, LLC | 2.48M | 7.2% | SCHEDULE 13G/A ↗ |
| May 14, 2026 | SCHEDULE 13G/A (amended) | FENC Fennec Pharmaceuticals Inc. | Rosalind Master Fund L.P. | 2.91M | 8.4% | SCHEDULE 13G/A ↗ |
| May 14, 2026 | SCHEDULE 13G/A (amended) | FENC Fennec Pharmaceuticals Inc. | Aharon Gil | 2.97M | 8.6% | SCHEDULE 13G/A ↗ |
| May 14, 2026 | SCHEDULE 13G/A (amended) | FENC Fennec Pharmaceuticals Inc. | Salamon Steven A J | 2.97M | 8.6% | SCHEDULE 13G/A ↗ |
| May 14, 2026 | SCHEDULE 13G/A (amended) | FENC Fennec Pharmaceuticals Inc. | Rosalind Advisors, Inc. | 3.04M | 8.8% | SCHEDULE 13G/A ↗ |
| Apr 28, 2026 | SCHEDULE 13G | FENC Fennec Pharmaceuticals Inc. | AIGH Capital Management LLC | 1.98M | 5.7% | SCHEDULE 13G ↗ |
| Apr 28, 2026 | SCHEDULE 13G | FENC Fennec Pharmaceuticals Inc. | Orin Hirschman | 1.98M | 5.7% | SCHEDULE 13G ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | FENC Fennec Pharmaceuticals Inc. | Lawrence Kam | 2.80M | 8.2% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | FENC Fennec Pharmaceuticals Inc. | Sonic GP LLC | 2.61M | 7.6% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | FENC Fennec Pharmaceuticals Inc. | Sonic Fund II, L.P. | 2.61M | 7.6% | SCHEDULE 13G/A ↗ |
| Feb 11, 2026 | SCHEDULE 13G/A (amended) | FENC Fennec Pharmaceuticals Inc. | Rosalind Master Fund L.P. | 2.61M | 9.3% | SCHEDULE 13G/A ↗ |
| Feb 11, 2026 | SCHEDULE 13G/A (amended) | FENC Fennec Pharmaceuticals Inc. | Aharon Gil | 2.68M | 9.5% | SCHEDULE 13G/A ↗ |
| Feb 11, 2026 | SCHEDULE 13G/A (amended) | FENC Fennec Pharmaceuticals Inc. | Salamon Steven A J | 2.68M | 9.5% | SCHEDULE 13G/A ↗ |
| Feb 11, 2026 | SCHEDULE 13G/A (amended) | FENC Fennec Pharmaceuticals Inc. | Rosalind Advisors, Inc. | 2.75M | 9.8% | SCHEDULE 13G/A ↗ |
| Jan 14, 2026 | SCHEDULE 13G/A (amended) | FENC Fennec Pharmaceuticals Inc. | John S. Clark II | 2.74M | 8.0% | SCHEDULE 13G/A ↗ |
| Jan 14, 2026 | SCHEDULE 13G/A (amended) | FENC Fennec Pharmaceuticals Inc. | Southpoint GP, LLC | 2.74M | 8.0% | SCHEDULE 13G/A ↗ |
| Jan 14, 2026 | SCHEDULE 13G/A (amended) | FENC Fennec Pharmaceuticals Inc. | Southpoint GP, LP | 2.74M | 8.0% | SCHEDULE 13G/A ↗ |
| Jan 14, 2026 | SCHEDULE 13G/A (amended) | FENC Fennec Pharmaceuticals Inc. | Southpoint Capital Advisors LLC | 2.74M | 8.0% | SCHEDULE 13G/A ↗ |
| Jan 14, 2026 | SCHEDULE 13G/A (amended) | FENC Fennec Pharmaceuticals Inc. | Southpoint Capital Advisors LP | 2.74M | 8.0% | SCHEDULE 13G/A ↗ |
| Jan 14, 2026 | SCHEDULE 13G/A (amended) | FENC Fennec Pharmaceuticals Inc. | Southpoint Master Fund, LP | 2.74M | 8.0% | SCHEDULE 13G/A ↗ |
| Nov 13, 2025 | SCHEDULE 13G | FENC Fennec Pharmaceuticals Inc. | Rosalind Master Fund L.P. | 2.08M | 7.5% | SCHEDULE 13G ↗ |
| Nov 13, 2025 | SCHEDULE 13G | FENC Fennec Pharmaceuticals Inc. | Aharon Gil | 2.08M | 7.5% | SCHEDULE 13G ↗ |
| Nov 13, 2025 | SCHEDULE 13G | FENC Fennec Pharmaceuticals Inc. | Salamon Steven A J | 2.08M | 7.5% | SCHEDULE 13G ↗ |
| Nov 13, 2025 | SCHEDULE 13G | FENC Fennec Pharmaceuticals Inc. | Rosalind Advisors, Inc. | 2.08M | 7.5% | SCHEDULE 13G ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | FENC Fennec Pharmaceuticals Inc. | Frederick Tucker Golden | 2.25M | 8.2% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | FENC Fennec Pharmaceuticals Inc. | Solas Capital Management, LLC | 2.25M | 8.2% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | FENC Fennec Pharmaceuticals Inc. | Dov Gertzulin | 1.11M | 4.1% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | FENC Fennec Pharmaceuticals Inc. | DG Value Partners II Master Fund, LP | 953,407 | 3.5% | SCHEDULE 13G/A ↗ |
| Feb 14, 2025 | SCHEDULE 13G/A (amended) | FENC Fennec Pharmaceuticals Inc. | DG Capital Management, LLC | 1.11M | 4.1% | SCHEDULE 13G/A ↗ |
44 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 6:01 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances